| Protocol No | Phase | Title | Total No of Participants | Year |
|---|---|---|---|---|
| 444563/013 (Rota-013) | II | A phase II, randomized, double-blind, placebo-controlled study of the safety, reactogenicity and immunogenicity of two or three doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine (RIX4414) at different viral concentrations (105.0 ffu and 106.0 ffu) in healthy infants (approximately 6 weeks old) in South Africa. | 85 | 2003 - 2004 |
| 759346/007 (DTPwHB/HibMenACTT007) | III | A phase III, open, randomized, controlled primary vaccination study to demonstrate the non-inferiority of GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine when mixed extemporaneously and given as a single injection with GSK Biologicals’ TritanrixTM-HepB/HiberixTM with respect to the immunogenicity of the hepatitis B antigen, when administered to healthy infants at 6, 10 and 14 weeks of age after a birth dose of hepatitis B vaccine. | 51 | 2004-2005 |
| 102248/037 (Rota-037) Cohort 1 | III | A phase III, double-blind, randomized, placebo-controlled, multi-center study to assess the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants in South Africa. | 258 | 2005 -2007 |
| 104756 | III | A phase III open, single centre booster vaccination study to assess safety and reactogenicity of a dose of DTPw-HBV/Hib vaccine given at 15-18 months of age and to assess the immunogenicity, safety and reactogenicity of a dose of MencevaxTM ACW vaccine given at 24 to 30 months of age in subjects primed in study 759346/007 | 43 | 2006 -2007 |
| 444563/022 (Rota-022) | II | A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa | 20 | 2005 -2008 |
| 102248/037 (Rota-037) Cohort 2 | III | A phase III, double-blind, randomized, placebo-controlled, multi-center study to assess the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants in South Africa. | 215 | 2006 – 2007 |
| IPM 100 | Epidemio- logical | A Cross-Sectional And Prospective, Observational, Cohort Study To Estimate HIV Incidence Among Sexually Active Adult Females | 800 | 2007 -2008 |
| 111274/037 (Rota-037) Cohort 2 Year 2 extension | III | A phase III, double-blind, randomized, placebo-controlled, multi-center study to assess the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants in South Africa. | 173 | 2007 - 2008 |
| CFAM810A2310 | III | A randomised, multicentre, double-blind study to compare the efficacy of single-day treatment (1000mg b.i.d) with Famciclovir compared to that of placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients | 6 | 2008 |
| CSPA100A2305 | III | An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension | 3 | 2009 |
| IPM014B | II | A double-blind, randomized, placebo-controlled phase I/II study to evaluate the safety and acceptability of dapivirine gel 4789, 0.05% 2.5g, a vaginal microbicide, conducted using daily monitored adherence in healthy HIV-negative women | 36 | 2009-2010 |
| IPM014A | II | A double-blind, randomized, placebo-controlled phase I/II study to evaluate the safety and acceptability of dapivirine gel 4759, 0.05% 2.5g, a vaginal microbicide, conducted using daily monitored adherence in healthy HIV-negative women | 40 | 2010 |
| IPM 015 | II | A double-blind, randomized, placebo-controlled phase I/II study to evaluate the safety of an intravaginal matrix ring with dapivirine in healthy HIV-negative women | 40 | 2010 |
| REMoxTB | III | A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol, isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis | 52 | 2010 - 2013 |
| IPM 027 | III | A Multi-centre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-negative Women | 482 | 2012 – 2016 |
| IPM 007 | Epidemiologica | A long-term follow-up cohort study of HIV infection in participants who seroconvert after enrolment in Dapivirine Vaginal Ring trials | 24 | 2012 - 2020 |
| EXSCEL | III | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with exenatide once weekly in Patients with Type 2 Diabetes Mellitus | 3 | 2015 - 2017 |
| STAND (NC-006) | III | A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA-824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis. | 8 | 2015 – 2018 |
| IPM 032 | IIIB | A Follow-On, Open-Label Trial To Assess Continued Safety Of and Adherence To The Dapivirine (25 Mg) Vaginal Ring-004 In Healthy, HIV-Negative Women | 234 | 2016 – 2019 |
| ECHO | IV | A Multi Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate (DMPA), Levonorgestrel (LNG) Implant, and Copper Intrauterine Devices (IUDs) | 407 | 2016 – 2019 |
| SimpliciTB (NC-008) | IIB | An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline plus Pretomanid plus Moxifloxacin plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants with Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants with Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB) | 32 | 2018 – 2022 |
| 2019nCOV-501 | II A/B | A Phase 2a/b, randomized, observer-blinded, placebo controlled study to evaluate the efficacy, immunogenicity, and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant in South African adult subjects living without HIV; and safety and immunogenicity in adults living with HIV | 207 | 2020 - 2022 |
| MK8591-022 (IMPOWER-022) | III | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection | 88 | 2021 - current |
| Sinovac PRO-nCoV-3002 | III | A Multi-center, Randomized, Double-blind, Placebo-controlled Phase ? Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated (CoronaVac®) in Children and Adolescents Aged 6 months to 17 Years. | 450 | 2021 – 2023 |
| GS-US-412-5624 | III | A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection | 28 and enrolling | 2021 - current |
| GT-0918-US-3001 | III | A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Male Outpatients with Mild to Moderate COVID-19 Illness | 0 | 2021 – 2022 |
| C4671006 | II/III | A Phase 2/3, Randomized, Double-Blind, Double-Dummy, Placebocontrolled Study To Evaluate The Safety And Efficacy Of 2 Regimens Of Orally Administered Pf07321332/Ritonavir In Preventing Symptomatic SARS-CoV-2 Infection In Adult Household Contacts Of An Individual With Symptomatic COVID-19 | 1 | 2021 - 2022 |
| C4671002 | II/III | An Interventional Efficacy And Safety, Phase 2/3, Double-Blind, 2-Arm Study To Investigate Orally Administered Pf-07321332/Ritonavir Compared With Placebo In Nonhospitalized Symptomatic Adult Participants With COVID-19 Who Are At Low Risk Of Progressing To Severe Illness | 0 | 2022 |
| VAC18192RSV3002 | III | A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older | 35 and recruiting | 2022 - current |
| 2019-nCoV-505 | II | A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M™Adjuvant in People Living with HIV | 34 | 2022 - current |
| INSIGHT | N/A | A cohort for evaluation of open-label PrEP delivery and PrEP preferences among African women | 150 | 2023 - current |